Erlotinib (Tarceva) for advanced non-small cell lung cancer

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2005年 / 47卷 / 1205期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [1] The current situation:: Erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer
    Comis, RL
    ONCOLOGIST, 2005, 10 (07): : 467 - 470
  • [2] The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
    Perez-Soler, R
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4238S - 4240S
  • [3] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [4] Use review of Erlotinib in advanced non-small cell lung cancer
    Alvarez-Payero, M.
    Ucha-Samartin, M.
    Martinez-Lopez-de-Castro, N.
    Campelo-Sanchez, E.
    Alvarez-Seoane, J.
    Vazquez-Lopez, C.
    Inaraja-Bobo, M. T.
    Perez Parente, D.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 438 - 438
  • [5] Review of erlotinib in the treatment of advanced non-small cell lung cancer
    Ganjoo, Kristen N.
    Wakelee, Heather
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04): : 335 - 346
  • [6] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [7] Erlotinib in Advanced Non-small Cell Lung Cancer Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study
    Reck, Martin
    van Zandwijk, Nico
    Gridelli, Cesare
    Baliko, Zoltan
    Rischin, Danny
    Allan, Simon
    Krzakowski, Maciej
    Heigener, David
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1616 - 1622
  • [8] An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy
    Tiseo, Marcello
    Gridelli, Cesare
    Cascinu, Stefano
    Crino, Lucio
    Piantedosi, Franco Vito
    Grossi, Francesco
    Brandes, Alba A.
    Labianca, Roberto
    Siena, Salvatore
    Amoroso, Domenico
    Belvedere, Ornella
    Valentino, Brunello
    Bearz, Alessandra
    Venturino, Paola
    Ardizzoni, Andrea
    LUNG CANCER, 2009, 64 (02) : 199 - 206
  • [9] ERLOTINIB FOR CHINESE ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Wang, H-P
    Li, Z.
    Wang, M-Z
    Yi, X.
    RESPIROLOGY, 2011, 16 : 172 - 172
  • [10] Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
    Wang, Yongsheng
    Schmid-Bindert, Gerald
    Zhou, Caicun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2012, 4 (01) : 19 - 29
12345